Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S D Kemp

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Journal of Veterinary Internal Medicine|January 13, 2015
Histopathologic variation between liver lobes in dogsS D Kemp, K L Zimmerman, D L Panciera, et al.
Nature|October 14, 1993
Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencingB A Larder, A Kohli, P Kellam, et al.
Journal of Virology|May 30, 1998
A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2',3'-dideoxy-3'-thiacytidineS D Kemp, C Shi, S Bloor, et al.
Journal of Virology|September 1, 1996
Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibilityP R Harrigan, I Kinghorn, S Bloor, et al.
Journal of Veterinary Internal Medicine|November 25, 2014
A comparison of liver sampling techniques in dogsS D Kemp, K L Zimmerman, D L Panciera, et al.
Journal of Virology|June 7, 2002
A mutation in the 3' region of the human immunodeficiency virus type 1 reverse transcriptase (Y318F) associated with nonnucleoside reverse transcriptase inhibitor resistanceP Richard Harrigan, Mahboob Salim, David K Stammers, et al.
The Journal of Biological Chemistry|August 5, 1992
Biochemical studies on the reverse transcriptase and RNase H activities from human immunodeficiency virus strains resistant to 3'-azido-3'-deoxythymidineS F Lacey, J E Reardon, E S Furfine, et al.
Journal of Virology|September 1, 1996
Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative GroupB A Larder, A Kohli, S Bloor, et al.
AIDS (London, England)|July 14, 2000
Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samplesK Hertogs, S Bloor, S D Kemp, et al.
The Journal of Infectious Diseases|June 2, 1998
Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination therapy: association with therapy failureV Miller, A Phillips, C Rottmann, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Journal of Veterinary Internal Medicine|January 13, 2015
Histopathologic variation between liver lobes in dogsS D Kemp, K L Zimmerman, D L Panciera, et al.
Nature|October 14, 1993
Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencingB A Larder, A Kohli, P Kellam, et al.
Journal of Virology|May 30, 1998
A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2',3'-dideoxy-3'-thiacytidineS D Kemp, C Shi, S Bloor, et al.
Journal of Virology|September 1, 1996
Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibilityP R Harrigan, I Kinghorn, S Bloor, et al.
Journal of Veterinary Internal Medicine|November 25, 2014
A comparison of liver sampling techniques in dogsS D Kemp, K L Zimmerman, D L Panciera, et al.
Journal of Virology|June 7, 2002
A mutation in the 3' region of the human immunodeficiency virus type 1 reverse transcriptase (Y318F) associated with nonnucleoside reverse transcriptase inhibitor resistanceP Richard Harrigan, Mahboob Salim, David K Stammers, et al.
The Journal of Biological Chemistry|August 5, 1992
Biochemical studies on the reverse transcriptase and RNase H activities from human immunodeficiency virus strains resistant to 3'-azido-3'-deoxythymidineS F Lacey, J E Reardon, E S Furfine, et al.
Journal of Virology|September 1, 1996
Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative GroupB A Larder, A Kohli, S Bloor, et al.
AIDS (London, England)|July 14, 2000
Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samplesK Hertogs, S Bloor, S D Kemp, et al.
The Journal of Infectious Diseases|June 2, 1998
Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination therapy: association with therapy failureV Miller, A Phillips, C Rottmann, et al.
Pageof 3